Loading...
•
Mar 31, 2022
United Therapeutics Q1 2022 Earnings Report
United Therapeutics experienced revenue growth driven by Tyvaso, Orenitram, and Unituxin, with a significant increase in net income compared to the previous year.
Key Takeaways
United Therapeutics reported a 22% increase in total revenue to $461.9 million for the first quarter of 2022, compared to $379.1 million in the first quarter of 2021. Net income saw a substantial rise to $239.9 million, a 748% increase from $28.3 million in the same period last year. The company is progressing with its phase 3 studies and anticipates potential FDA approval for Tyvaso DPI.
Total revenue increased by 22% year-over-year, reaching $461.9 million.
Net income increased significantly to $239.9 million, up 748% from the previous year.
Tyvaso revenue grew by 40% due to increased quantities sold and label expansion.
The company is actively progressing seven phase 3 studies and awaiting the FDA's decision on Tyvaso DPI.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
United Therapeutics did not provide specific forward guidance in this report, but highlighted their goals of reaching 6,000 U.S. patients on Tyvaso by the end of 2022 and 25,000 patients on their therapies by the end of 2025.
Positive Outlook
- Continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease.
- Awaiting the FDA’s decision on Tyvaso DPI.
- Working toward reaching 6,000 patients on Tyvaso therapy by the end of 2022.
- Working toward reaching 25,000 patients on our therapies by the end of 2025.
- Progressing seven phase 3 studies.
Challenges Ahead
- FDA issued a complete response letter (CRL) from the FDA noting a single deficiency preventing approval of Tyvaso DPI, related to an open inspection issue at a third-party facility.
- The FDA had not yet completed its review of a Citizen Petition submitted to the FDA in July 2021 concerning the safety of an excipient in Tyvaso DPI.
- The FDA requested additional information concerning the pulmonary safety of Tyvaso DPI related to the Citizen's Petition.
- Decrease in U.S. Remodulin revenues was primarily due to a decrease in quantities sold.
- Increase in legal expenses related to litigation matters
Revenue & Expenses
Visualization of income flow from segment revenue to net income